| |
Financial Year 2008 - 2009
Quarter II
(September 2008)
Quarter I
(June 2008)
Financial Year 2007 - 2008
Quarter IV
(March 2008)
Quarter III
(December 2007)
Quarter II
(September 2007)
Quarter I
(June 2007)
Financial Year 2006 - 2007
Quarter IV
(March 2007)
Quarter III
(December 2006)
Quarter II
(September 2006)
Quarter I
(June 2006)
Financial Year 2005 - 2006
Quarter IV
(March 2006)
Quarter III
(December 2005)
Quarter II
(September 2005)
Quarter I
(June 2005)
Financial Year 2004 - 2005
Quarter IV
(March 2005)
Quarter III
(December 2004)
Quarter II
(September 2004)
Quarter I
(June 2004)
Financial Year 2003 - 2004
Quarter IV
(March 2004)
Quarter III
(December 2003)
Quarter II
(September 2003)
Quarter I
(June 2003)
Financial Year 2002 - 2003
Quarter IV
(March 2003)
Quarter III
(December 2002)
Quarter II
(September 2002)
Quarter I
(June 2002)
|
MATRIX LABORATORIES LIMITED
1-1-151/1, IV FLOOR, SAIRAM TOWERS, ALEXANDER ROAD SECUNDERABAD- 500 003
UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED
30th JUNE 2008
| (Rs.in Lakhs ) |
| Sl. No |
Particulars |
Quarter ended
30th June |
Year ended
31st March |
2008
(Un Audited) |
2007
(Un Audited) |
2008
(Audited) |
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
|
Net Sales / Income from Operations
-Sales(net)
-Other Income from Operations
-Income from Potential patent infringement suit
Total
Other Income
Total Income (1+2)
Expenditure
a) (Increase) / Decrease in Stock in trade and Work in Programs
b) Materials Consumed
c) Purchase of traded goods
d)Employee cost
e)Depreciation & Amortisation
f)Other Expenditure
Total Expenditure
Profit before R&D & Interest (3-4)
Research and Development Expenditure
Interest
Profit from Ordinary Activities before tax & Exceptional item (6-7-8)
Provision for impairment of goodwill (Refer note 3)
Profit/(Loss) before tax and after exceptional item (9-10)
Tax expense (net)
Profit /(Loss) after Tax & Exceptional Item before Minority Interest and share in Associate (11-12)
Less : Minority Interest
Less : Share of Profit/ (Loss) in Associate
Net Profit/ (Loss) after Tax and Exceptional Item (13-14-15)
Paid-up equity share capital (Face value - Rs.2 each)
Reserves excluding revaluation reserves
Earning Per Share (Not annualised) - (Face Value - Rs.2 each)
On Profit/(Loss) after Tax :
- Before Exceptional Item
-Basic
-Diluted
- After Exceptional Item
-Basic
-Diluted
|
53321
90
669
54080
654
54734
840
16127
10630
5968
1636
9056
44257
10477
5513
3057
1907
-
1907
1514
393
(21)
-
372
3092
-
0.24
0.24
0.24
0.24
|
44702
99
669
45470
953
46423
4250
12627
7768
4563
1493
7159
37860
8563
2920
2080
3563
-
3563
1075
2488
200
-
2688
3088
-
1.74
1.73
1.74
1.73
|
172807
661
2691
176159
2447
178606
(8168)
65967
32201
18825
6055
31989
146869
31737
14233
9604
7900
48712
(40812)
5297
(46109)
419
(3)
(45693)
3092
65388
1.96
1.95
(29.59)
(29.59)
|
Segment Information :
Segment Revenue :
- Pharmaceuticals
- Medical Supplies
Net Segment Revenue
Segment Results :
Profit before tax and interest from each segment
- Pharmaceuticals
- Medical Supplies
Total
Less:Interest
Total Profit before tax
Capital Employed
- Pharmaceuticals
- Medical Supplies
- Unallocated
Total Capital Employed
|
4838
4939
53321
4665
299
4964
(3057)
1907
173055
5656
85060
263771
|
40769
3933
44702
5421
222
5643
(2080)
3563
149483
4130
113842
267455
|
157067
15740
172807
16933
571
17504
(9604)
7900
156740
4825
79771
241336
|
|
| Notes : |
|
| 1. |
|
The above results were subjected to a limited review by the Auditors, reviewed by the Audit Committee and approved at the meeting of the Board of Directors of the Company held on 29th July 2008.
|
| 2. |
|
The figures for the previous year / period have been rearranged/regrouped wherever necessary to conform to current period's presentation. |
|
|
|
| For and on behalf of the Board |
|
| place: Secunderabad |
|
Jagdish Dore |
|
| Date: 29th July 2008 | |
Managing Director & Chief Executive Officer |
|
|
|
MATRIX LABORATORIES LIMITED
1-1-151/1, IV FLOOR, SAIRAM TOWERS, ALEXANDER ROAD SECUNDERABAD- 500 003
UNAUDITED FINANCIAL RESULTS FOR THE YEAR ENDED
30th JUNE 2008
| (Rs.in Lakhs ) |
| Sl. No |
Particulars |
Quarter ended 30th June |
Year ended 31st March |
2008
(unAudited) |
2007
(unAudited) |
2008
(Audited) |
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
|
Net Sales / Income from Operations
-Exports
-Domestic
-Other Income from Operations
-Income from Potential patent infringement suit
Total
Other Income
Total Income (1+2)
Expenditure
a) (Increase) / Decrease in Stock in trade and Work in Programs
b) Materials Consumed
c) Purchase of traded goods
d)Employee cost
e)Depreciation & Amortisation
f)Other Expenditure
Total Expenditure
Profit before R&D & Interest (3-5)
Research and Development Expenditure (including depreciation)
Interest
Profit from Ordinary Activities before Exceptional item & tax(5-6-7)
Provision for diminution in the value of investment in subsidiary (Refer note 3)
Profit/(Loss) before tax and after exceptional item (8-9)
Tax expense (net)
Net Profit/(Loss) after tax (10-11)
Paid-up equity share capital (Face value - Rs 2/- each)
Reserves excluding revaluation reserves
Earning Per Share (EPS) (Not annualised)
On Profit/(Loss) after Tax :
- Before Exceptional Item
- Basic
- Diluted
- After Exceptional Item
- Basic
- Diluted
Public shareholding
- Number of shares
- Percentage of shareholding
|
2372
7974
180
669
32555
458
33013
711
13875
662
2431
834
4487
23000
10013
4623
1045
4345
-
4345
1108
3237
3092
-
2.09
2.09
2.09
2.09
36,903,471
23.87% |
13449
7161
198
669
21447
747
22224
413
10105
5
1852
745
3404
16524
5700
2099
477
3124
-
3124
545
2579
3088
-
1.67
1.66
1.67
1.66
36,405,635
23.62% |
62066
31797
1322
2691
97876
2018
99894
(7258)
53367
354
7038
2954
15991
72446
27448
10641
2677
14130
40118
(25988)
3848
(29836)
3092
64899
6.66
6.64
(19.32)
(19.32)
36,876,696
23.85% |
|
| Notes : |
|
| 1. |
|
The above results were subjected to a limited review by the Auditors, reviewed by the Audit Committee and approved at the meeting of the Board of Directors of the Company held on 29th July 2008.
|
| 2. |
|
The activities of the Company relate to only one business segment i.e. Pharmaceuticals.
|
| 3. |
|
During the Quarter 26,775 Equity Shares of Rs.2 each at a premium of Rs.141.13 were alloted, on exercise of Stock Options under the Employee Stock Option Scheme-2004.
|
| 4. |
|
Tax expense includes Current tax Rs.489 lakhs (Quarter ended 30th June 2007 Rs.363 lakhs), Deferred Tax Rs.648 lakhs (Quarter ended 30th June 2007 Rs.475 lakhs), and Fringe benefit tax Rs.27 lakhs (Quarter ended 30th June 2007 Rs.70 lakhs) and is net of MAT credit available of Rs.56 lakhs (Quarter ended 30th June 2007 Rs.363 lakhs).
|
| 5. |
|
The figures for the previous year / period have been rearranged/regrouped wherever necessary to conform to current period's presentation.
|
| 6. |
|
Summary of Investor Complaints
|
|
|
Opening : Nil , Received during the quarter : 3 , Resolved : 3 , Closing : Nil.
|
|
|
|
| For and on behalf of the Board |
|
| place: Secunderabad |
|
Jagdish Dore |
|
| Date: 29th July 2008 | |
Managing Director & Chief Executive Officer |
|
|
|
|
|
